Creative Edge Nutrition Inc (OTCMKTS:FITX) released a letter to its shareholders pertaining to the details related with the re-filing of license application for judicial review. The purpose of the letter was to briefly address the dismissal of the license applications for Judicial Review filed in Canadian Federal Court.
The details
Creative Edge stated that in no way the rejection of the Application is an indication that it has abandoned its pursuit for judicial relief. Health Canada had rejected the company’s application license under the ‘MMPR Program’. The rejection is merely a procedural problem to fulfill certain procedural rules as led by the Court.
CEN Biotech
Creative Edge established CEN Biotech in 2013 as its partially owned subsidiary firm. It was created for the sole objective of providing the Canadian public with Pharma-grade medical cannabis under the MMPR program. The subsidiary submitted a comprehensive license application to become a LP of dried marihuana for medical purposes.
Another letter
Creative Edge has been releasing a series of letters to its shareholders to inform them about the latest happenings related with application under the MMPR program. In latest letter, the company said that CEN Biotech has been a target of tiresome attacks in past twelve months. It mentioned the name of a Canadian newspaper, The Globe and Mail, and stated it responsible for attacking the company.
The problems
Creative Edge Nutrition Inc (OTCMKTS:FITX) mentioned the name of Grant Robertson who is a reporter for The Globe and Mail responsible for the campaign of untruths and image distortion. The company said that a major part of attacks came from the mentioned newspaper. The objective was just to destroy the image and reputation of the company that management has created by strenuous efforts. The reporter made false accusations against Creative Edge and its subsidiary. On Thursday’s trading session, the stock price of Creative Edge dropped 16.67% to close the trading session at $0.00500.
